Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Healthy short stature.

Archives of endocrinology and metabolism·2026
Same author

The neurobiological cravings signature (NCS) as a predictive neuromarker of clinical outcomes in alcohol use disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Long-acting Growth Hormone Preparations.

Endocrinology and metabolism clinics of North America·2025
Same author

Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases.

Physiology (Bethesda, Md.)·2025
Same author

The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorder: a randomized, placebo-controlled clinical trial.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2025
Same author

Neural correlates of choosing alcohol over a palatable food reward in humans.

Alcohol, clinical & experimental research·2025

Related Experiment Video

Updated: May 30, 2026

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis
06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

Short children born prematurely: data from KIGS.

Margaret C S Boguszewski1, Hanna Karlsson, Patrick Wilton

  • 1Pediatric Endocrinology Unit, Department of Pediatrics, Federal University of Paraná, Curitiba, Brazil. margabogus@uol.com.br

Hormone Research in Paediatrics
|July 23, 2011
PubMed
Summary
This summary is machine-generated.

Children born prematurely who experience growth failure may benefit from growth hormone (GH) therapy. The Pfizer International Growth Database (KIGS) tracks growth responses in these young patients.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Related Experiment Videos

Last Updated: May 30, 2026

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis
06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Area of Science:

  • Pediatrics
  • Endocrinology
  • Neonatology

Background:

  • Neonatal care advances improve survival for extremely preterm infants.
  • Some premature infants experience growth failure and short stature.
  • Growth hormone (GH) therapy is a potential treatment for these children.

Purpose of the Study:

  • To gather data on premature children receiving GH therapy.
  • To analyze information from the Pfizer International Growth Database (KIGS).

Main Methods:

  • KIGS database queried for prepubertal short children (height <-2 SDS).
  • Inclusion criteria: gestational age <37 weeks and available birth weight.
  • Patients classified by gestational age (preterm, very preterm) and birth weight (AGA, SGA).

Main Results:

  • 3,215 patients were analyzed.
  • Subgroups included preterm AGA (1,928), very preterm AGA (629), preterm SGA (519), and very preterm SGA (139).

Conclusions:

  • KIGS database facilitates evaluation of GH therapy effects.
  • Growth response can be assessed in premature children with varying characteristics.
  • Database supports research on growth patterns and GH therapy in preterm populations.